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Abstract 
AmpC beta-lactamase is an enzyme commonly produced by E. coli that causes resistance to 
cephalosporins and penicillins. Enzyme production is controlled by the strength of the 
promoter encoded by the chromosomal ampC gene, with the level of production affected by 
the presence of certain mutations in this region. This study set out to determine the 
prevalence of ampC promoter mutations present in a group of uropathogenic E. coli strains. 
 
A total of 50 clinical strains of E. coli were collected from urine samples between June 2011 
and November 2011. Strains were investigated for the presence of mutations in the 
chromosomal ampC promoter region by amplification and sequencing of a 271bp product. 
The presence of ampC-carrying plasmids derived from other species was also determined, to 
exclude these from further analysis. 
 
ampC-carrying plasmids were found in 10 of the 50 strains, all of which were of the CIT-type. 
Analysis of the chromosomal ampC promoter region in the 40 remaining strains showed 
mutations at 16 different positions, with 18 different genotype patterns detected overall. 
The most common ampC chromosomal mutation, present in 25 of 40 strains, was a T→A 
transition at position -32. This mutation has been shown by others to increase enzyme 
production by up to 46-fold. 
 
Altogether, three separate mutations (-32, -42 and -13ins) were present in 90% of the 40 
non-plasmid strains, indicating a strong association with the resistance observed. It appears, 
therefore, that the majority of AmpC-mediated resistance in E. coli can be accounted for by 
just three point mutations in the chromosome. 
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Introduction 
AmpC beta-lactamase is an enzyme commonly produced by Escherichia coli that causes 
resistance to cephalosporins and penicillins.1 All strains of E. coli carry the chromosomal 
ampC gene for enzyme production, which is normally weakly expressed and under tight 
control by regulatory mechanisms.2 Production of the chromosomally-encoded enzyme is 
constitutive, but at such a low level that clinical failure of beta-lactam antibiotics is not 
usually seen. Certain mutations can occur in the promoter region, affecting the level of 
enzyme production. Strains with chromosomal ampC mutations can produce enzymes in 
higher amounts and are said to hyper-produce the AmpC enzyme, leading to clinical 
resistance and treatment failures.3  
 
The common DNA sequence seen in numerous E. coli promoters is a -35 box (TTGACA) 
separated from a -10 box (TATAAT) by 17bp.2 The normal ampC promoter sequence, 
however, includes single nucleotide difference in each of these hexameric boxes, together 
with a spacer difference of 16bp (Figure 1). These small differences are sufficient to affect 
the function of the promoter and decrease the normal AmpC enzyme production to its 
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constitutive low level.4 
 
Mutations in the ampC promoter region can arise, and include transitions and insertions in 
the -35 or -10 boxes, which create a region more closely related to the standard E. coli 
promoter sequence, and thus a stronger promoter.2 The most frequently reported promoter 
mutation (C→T at position -42) is one that creates a displaced -35 box in the promoter 
sequence, and is associated with a 20-fold increase in enzyme production.5 Other reported 
key mutations include substitutions that change the sequence of the wild-type -35 box itself, 
and insertions in the spacer region between the -35 and -10 boxes. Mutations have also 
been reported throughout other locations in the promoter, attenuator and coding regions, 
but these are considered to have a lesser impact on the level of enzyme production.5 
 
In addition to chromosomal ampC mutations, E. coli can also acquire the genes for AmpC 
enzyme production from other species. First described in 1988, plasmid ampC genes are 
derived from species such as Enterobacter spp. and Citrobacter spp..6 Although there are 
>200 different plasmids reported to carry ampC genes, for convenience they are usually 
classified into six groups based on the species of origin; CIT, ACC, DHA, FOX, MOX, and EBC.7 
The CMY-2 plasmid (within the CIT group) is the most common AmpC plasmid encountered 
to date, and also has the largest geographic spread.1 Woodford et al. (2007)8 tested 135 
strains of E. coli referred from UK laboratories for the investigation of unusual resistance 
patterns, detecting an ampC-carrying plasmid in 49%. The majority were determined to be 
of the CIT-group, but ACC, FOX and DHA groups were also detected. Strains with plasmids 
carrying ampC genes were found to be more resistant to third-generation cephalosporins 
than those with ampC chromosomal promoter mutations. 
 
This study set out to characterise the chromosomal ampC mutations present in a group of 
uropathogenic E. coli strains. Although E. coli is one of the most common pathogens isolated 
in clinical laboratories, there is a lack of data for the UK describing the prevalence and 
nature of AmpC resistance in clinical isolates. This is particularly the case for the 
chromosomal mutations responsible for AmpC enzyme hyper-production. Whilst the ampC-
carrying plasmids can give rise to a higher level of resistance, the chromosomal ampC 
mutations seen in E. coli represent a larger overall group of resistant strains. 
 
Materials & Methods 
Strain Collection 
Clinical strains of E. coli isolated from urine samples in the Gloucestershire laboratory 
between June 2011 and November 2011 were included if disc susceptibility testing indicated 
cefpodoxime resistance with a subsequent negative result for clavulanic acid synergy; thus 
excluding the presence of ESBL-mediated resistance.9 Strains were identified to species level 
using a chromogenic urine media plate (257481, Becton Dickinson, Oxford, UK) and API20E 
identification strips (20100, Biomerieux, Basingstoke, UK). Isolates were excluded if the 
same species had previously been isolated from the patient within a 28-day period. Strains 
were anonymised before inclusion in the study, and only basic patient demographic data 
(e.g. age and gender) were collected for each sample. During the collection period, a total of 
50 clinical urine strains were included. 
 
Susceptibility Testing 
4 
Strains were tested for susceptibility to a range of cephalosporins, including the antibiotics 
cefpodoxime (10µg), cefuroxime (30µg), cefoxitin (30µg), cefotaxime (30µg) and cefepime 
(30µg), using a standardised disc susceptibility method.10 A 0.5 MacFarland suspension was 
prepared and diluted to a 1:100 concentration. The final suspension was inoculated onto an 
Isosensitest agar plate (PO0779A, Oxoid, Basingstoke, UK) using a cotton-tipped swab. 
Antibiotic discs (various, Oxoid, Basingstoke, UK) were applied to the surface of the agar and 
the plate was incubated for 18-24 hours at 37oC in air. Following incubation, the zone size 
for each antibiotic disc was recorded. 
 
Strains were also tested to determine the minimum inhibitory concentration (MIC) of 
cefotaxime. MICE gradient strips (MA0111F, Oxoid, Basingstoke, UK) were used to test the 
cefotaxime MIC within the range 0.002 to 32mg/L. A 0.5 MacFarland suspension was 
prepared and inoculated directly onto an Isosensitest agar plate using a cotton-tipped swab. 
The MICE strip was applied to the surface of the agar and the plate was incubated for 18-24 
hours at 37oC in air. Following incubation, the point of intersection of the zone to the strip 
was recorded as the MIC for the strain. 
 
Detection of ampC Plasmids 
DNA templates for PCR amplification were prepared using a crude-lysis method.11 Strains 
were incubated overnight on Columbia Horse Blood agar plates (PB0122A, Oxoid, 
Basingstoke, UK). A heavy bacterial suspension, equivalent to MacFarland standard 4.0, was 
prepared in 100µl water. Tubes were vortex-mixed for 2 minutes and then centrifuged for 5 
minutes at 8,000g. The resulting supernatants were used as the DNA template. 
 
PCR assays were run on the SmartCycler II instrument (Cepheid, Sunnyvale, US), using the 
DX software (Version 3.0). Assay parameters were those recommended for use with the 
Quantifast SYBR Green master-mix (204054, Qiagen, Manchester, UK): 95oC for 5 minutes, 
followed by 35 cycles of 95oC for 10 seconds and 60oC for 30 seconds. Fluorescence was 
read after each cycle at the instrument settings for FAM dye. A melting curve protocol was 
run at the end of amplification, with the temperature increasing from 60oC to 95oC at a rate 
of 0.5oC / sec. The resulting dissociation curve was used to visualise the presence of an 
amplified product. 
 
The presence of AmpC plasmid groups was determined using two multiplex real-time SYBR 
Green PCR assays (CIT/ACC/DHA and FOX/MOX/EBC). Primers for five of the plasmid groups 
were as previously described.7 The CIT primers were updated to include more recently 
reported plasmids: CIT-F (5’-TGA TGC AGG AGC AGG CTA TTC-3’) and CIT-R (5’-ACA GAC CAA 
TGC TGG AGT TAG-3’). Primers (Invitrogen, Paisley, UK) were used at a 0.2µM final 
concentration. Multiplex AmpC plasmid assays with positive dissociation curves were 
confirmed using the same primers in three separate simplex reactions, to identify the 
individual plasmid present.  
 
Sequencing the ampC Promoter Region 
A 271bp region of the ampC gene, including the promoter region, attenuator region and 
part of the coding region, was amplified for each isolate using previously published primers 
at 0.1µM concentration.3 PCR protocol parameters were: 95oC for 5 minutes, followed by 35 
cycles of 95oC for 10 seconds and 60oC for 30 seconds. A melting curve protocol was run to 
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confirm the presence of an amplified product prior to sequencing. PCR products were sent 
to an external company (Eurofins Genomics, Ebersberg, Germany) for purification and 
sequencing, using the forward amplification primer. The reported sequence of each product 
was compared against the GenBank entry for E. coli NCTC 12241 (GenBank Accession 
AY899338), a laboratory control strain. Sequences were aligned using the ClustalW online 
software (www.ebi.ac.uk/tools/msa/clustalw2). The nature and position of each mutation 
was noted, and recorded according to the numbering system of Jaurin et al. (1981).12 
 
Results 
The 50 collected strains comprised 75% from female patients, and 25% from male. The 
mean age of patients was 58.3 years, with a range from 1 to 94 years. The results for disc 
susceptibility testing are shown in Table 1. The majority (98%) of isolates were resistant to 
cefuroxime when zone sizes were compared against breakpoints set by the British Society of 
Antimicrobial Chemotherapy (BSAC).10 In contrast, only 28% of strains demonstrated 
resistance to cefotaxime. Results also showed 98% of strains were resistant to cefoxitin, and 
there were 22 strains (44%) with resistant or intermediate zone sizes to the fourth-
generation cephalosporin cefepime.  
 
Ten strains demonstrated an amplification product typical of the CIT group of plasmids. 
None of the other plasmid groups (ACC, DHA, FOX, MOX, EBC) were detected. As the genes 
carried on AmpC plasmids can account for enzyme production alone, these strains were 
excluded from further analysis. 
 
From the remaining 40 strains, sequencing the 271bp region covering the chromosomal 
ampC promoter showed mutations at 16 different positions throughout the amplified region 
(See Table 2). Overall, 18 different genotype patterns were detected from the 40 strains 
investigated, with all strains containing at least one polymorphism when compared to the 
sequence for the E. coli control strain. The most common chromosomal ampC genotype 
(n=11) included a T→A substitution at position -32, together with substitutions at positions 
+58 and +63. The -32 mutation alters the wild-type -35 box from TTGTCA to TTGACA, one 
that is closer to the E. coli standard promoter sequence.5 The altered -35 box retains its 
original position in the promoter region. Mutations related to a displaced promoter region 
were found in three strains, at positions -42 and -18. The -42 (C→T) substitution creates a 
new -35 box, whereas the G→A mutation at -18 gives rise to a new -10 box region. These 
mutations are often reported together,13 and result in two new regions 17bp apart at 
different locations. The increased distance between the two regions has been reported to 
affect promoter strength.5 The -18 mutation was also observed in two strains without the -
42 mutation present. 
 
Insertions in the spacer region (position -13) were detected in eight strains, increasing the 
distance between the -35 and -10 boxes from 16bp through the insertion of 1 or 2 base 
pairs. Seven strains had mutations in the attenuator region (positions +17, +23 and +37), 
often present along with promoter mutations. A total of 19 strains were found to have 
mutations in the coding region. The three mutations at positions +63, +70 and +81 have 
been reported to alter the amino acid coded for at each of the three respective codons. 
However, it is not clear whether this has a significant impact on enzyme function.13 
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The geometric mean MIC for cefotaxime was 1.2mg/L for all strains, just above the 
recommended breakpoint of 1.0mg/L.10 Those strains with the -32 mutation present had a 
lower cefotaxime MIC of 0.6mg/L, compared to 1.2mg/L for strains with other mutations. In 
contrast, the ten strains with a CIT plasmid present had a geometric mean cefotaxime MIC 
of 7.3mg/L. 
 
Discussion 
CIT-type plasmids were found in 20% of the 50 strains collected. Although not fully 
characterised in this study, these are usually reported to be the CMY-2 plasmid. The 
presence of CMY-2 plasmids has been reported globally in clinical samples, and has also 
been associated with foodstuffs and animals.14–16 Phylogenetic studies have shown that E. 
coli strains carrying AmpC plasmids are more likely to be virulent, pathogenic types, 
whereas the strains with chromosomal promoter mutations are more likely to be 
commensal or environmental strains.17 
 
A total of 28 (70%) of the remaining 40 strains possessed either the -42 or -32 mutation, 
both considered to be key factors in creating a stronger ampC promoter by creating a -35 
box with greater homology to the E. coli standard promoter sequence.5 The -32 mutation 
was predominant in this study, with 25 strains demonstrating this substitution, either alone 
or in conjunction with other mutations. This mutation has been reported to result in an 8- to 
46-fold increase in over-expression when compared to wild type strains.5 In this study, the 
geometric mean MIC for cefotaxime in the -32 mutation group was 0.6mg/L, compared to 
0.06mg/L for the E. coli control strain (NCTC 12241), showing a ten-fold increase. 
 
The -42 mutation and -13 spacer insertions have been shown to effect a similar impact on 
the level of over-expression; 20-fold and 24- to 61-fold, respectively.5 Whilst we found only 
three strains with the -42 mutation, other studies have reported a higher prevalence,13,17–19 
with one study finding 100% of isolates with this mutation.20 Eight of the 40 strains in our 
study had insertions of either one or two bases at position -13. The inserted bases were 
either adenine or thymine, and increased the spacer region from 16 base pairs to 17 or 18 
base pairs. Seven strains were found to have mutations in the attenuator region. Although 
attenuator region mutations are thought to increase enzyme production through the 
destabilisation of the stem-loop structure, Tracz et al. (2007) demonstrated that these 
mutations have little actual affect on the level of enzyme production.5 
 
Resistance to cefoxitin is proposed as a screening test for AmpC production.10 In this study, 
98% of all strains were resistant by disc susceptibility testing, confirming it’s utility as such. 
Whilst this may represent a good method for detecting AmpC-mediated resistance, the 
specificity of the method is reduced by other means in which strains can become resistant 
to cefoxitin (e.g. membrane permeability).21 AmpC-producing strains are generally 
considered to have the antibiogram phenotype of cefoxitin-resistant, cefepime-sensitive.8 
Here, only 56% of strains met the criteria for both, with only 42% having a zone size above 
the breakpoint of 32mm for cefepime susceptibility.                                                                                                                                                                              
 
In this study of 50 uropathogenic strains of cefpodoxime-resistant, ESBL-negative E. coli, 
AmpC beta-lactamase resistance was confirmed in 92% of isolates. Although some strains 
did carry a plasmid ampC gene, the majority of strains possessed one of the ampC 
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chromosomal promoter region mutations recognised to cause enzyme hyper-production. 
The -32 mutation, -42 mutation and -13 insertions accounted for 90% of the resistance in 
the 40 non-plasmid strains, but were not found together in the same strain. Thus, providing 
further evidence that these represent the key mutations responsible for enzyme hyper-
production. It was of interest to note a predominance of the -32 mutation in the strains, 
rather than the -42 mutation reported elsewhere. Although unlikely to represent a 
difference in the level of clinical resistance, strains carrying the -32 mutation may represent 
a dominant clone in the local population. Further studies are underway to include strains 
from other laboratories and to utilise molecular typing methods to identify the presence of 
different resistant strain populations.   
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Figure 1: Section of ampC promoter region, showing the positions of: 
a) The wild-type hexameric -10 and -35 boxes 
b) C->T transition at position -42 creates a displaced -35 box with a sequence identical to the E. coli 
standard promoter (TTGACA) 
c) T->A transition at position -32 creates an altered wild-type -35 box with a sequence identical to the E. 
coli standard promoter (TTGACA) 
d) Insertion of a single nucleotide at position -13 increases the spacer distance from 16bp to 17bp 
Numbering of positions is according to Jaurin et al. (1981)
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 Disc 
Content 
(μg) 
Zone 
Diameter 
Breakpoints 
(mm) 
S (%) I (%) R (%) 
Cefpodoxime 10 ≤19 0 (0) N/A 50 (100) 
Cefuroxime 30 ≤19 1 (2) N/A 49 (98) 
Cefotaxime 30 ≤23 to ≤29 14 (28) 22 (44) 14 (28) 
Cefoxitin 30 ≤22 1 (2) N/A 49 (98) 
Cefepime 30 ≤26 to ≤31 28 (56) 12 (24) 10 (20) 
Table 1: Disc susceptibility results for the 50 strains to a range of five cephalosporins. The zone diameter 
breakpoints shown are for resistant strains, or for resistant and intermediate strains if a range is given. 
S = Resistant, I = Intermediate, R = Resistant
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Table 2: Details of mutations observed at different positions in the amplified 271bp region of the promoter, attenuator and coding regions of the ampC gene. Each 
genotype is shown, with the corresponding numbers of strains allocated to that group. Genotype numbers were allocated within this study. Position numbers for 
locations on the ampC gene were those used by Jaurin et al. (1981).
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 The control sequence is derived from the GenBank entry for E. coli NCTC 12241 (AY899338). 
ins = 1 or 2 bp insertions at position -13. 
Genotype No. of Strains -42 -32 -28 -18 -14 -13 -13ins -1 +6 +17 +23 +34 +37 +58 +63 +70 +81 
Control  C T G G T T - C C C G G G C T C A 
G1 11  A            T C   
G2 8  A                
G3 2  A              T G 
G4 2       T  T         
G5 2 T   A    T      T   G 
G6 2   A    AT           
G7 2   A  A  T   T        
G8 1    A    T      T   G 
G9 1   A               
G10 1   A    T           
G11 1      G TT           
G12 1  A A       T        
G13 1  A A               
G14 1  A  A    T   A   T   G 
G15 1  A           A   T G 
G16 1 T   A    T   A   T   G 
G17 1   A         A  T    
G18 1   A       T        
